Oncopeptides AB (publ) (ONPPF PINK) stock market data APIs
$0.264
0(0%)
as of March 19, 2025
Oncopeptides AB (publ) Financial Data Overview
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Prev. Close
0.264
Open
0.264
High
0.264
Low
0.264
52 wk Range
0.265-0.6
Market Cap
55 985 K
Shares Outstanding
211 M
Revenue
31 648 K
Beta
-0.448
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncopeptides AB (publ) data using free add-ons & libraries
Get Oncopeptides AB (publ) Fundamental Data
Oncopeptides AB (publ) Fundamental data includes:
- Net Revenue: 31 648 K
- EBITDA: -281 060 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-25
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncopeptides AB (publ) News
New
Oncopeptides Chief Financial Officer Holger Lembrer takes office today
STOCKHOLM, Jan. 18, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat...
Oncopeptides appoints Holger Lembrer as Chief Financial Officer
STOCKHOLM, Jan. 11, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological dise...
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
STOCKHOLM, Jan. 4, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological disea...
Oncopeptides has announced the Nomination Committee
STOCKHOLM, Dec. 22, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nom...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
